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Abstract 
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disease affecting women of reproductive 
age and associated with reproductive and metabolic dysfunction. Few studies are available regarding metabolic traits 
in Brazilian women with PCOS. The aim of this systematic review and meta-analysis was to summarize the available 
evidence regarding metabolic traits and comorbidities in Brazilian women with polycystic ovary syndrome (PCOS).
Methods: We systematically searched PubMed, Cochrane Central Register of Controlled Trials, and Embase for cross-
sectional, case–control, or cohort studies focusing on populations of different regions from Brazil, published until 
July 31, 2019. Studies were selected if they reported PCOS diagnostic criteria. Studies without a control group were 
included if they presented relevant metabolic data.
Results: Of 4856 studies initially identified, 27 were included in the systematic review and 12 were included in the 
meta-analysis, for a total of 995 women with PCOS defined by Rotterdam criteria and 2275 controls from different 
regions of Brazil. Obesity, metabolic syndrome and IGT were prevalent, and standard mean differences for BMI (SMD 
0.67, 95% CI, 0.29, 1.05), waist circumference (SMD 0.22, 95% CI 0.02, 0.41), systolic (SMD 0.66, 95% CI 0.30, 1.01) and 
diastolic blood pressure (SMD 0.55, 95% CI 0.24, 0.87), glucose (SMD 0.21, 95% CI 0.04, 0.38) and HOMA (SMD 0.78, 95% 
CI 0.52, 1.04) were significantly higher in Brazilian women with PCOS compared to controls. Lipid profile was more 
adverse in PCOS vs. non-PCOS women. Between-study heterogeneities were low/moderate for glucose and HOMA 
and moderate/high for the other variables.
Conclusions: The data of this systematic review and meta-analysis indicate that Brazilian women with PCOS have a 
worse metabolic profile than women without PCOS with no important regional differences. The prevalence of meta-
bolic changes is intermediate in Brazil vs. other countries.
Keywords: Polycystic ovary syndrome, Obesity, Blood pressure, Insulin resistance, Metabolic abnormalities, Brazil
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Polycystic ovary syndrome (PCOS) is the most common 
endocrine disorder among women of reproductive age [1, 
2]. Despite an uncertain etiology, there is strong evidence 
that complex interactions between genetic, environmen-
tal, and behavioral factors contribute to the onset and 
to the heterogeneous expression of the syndrome [3]. In 
fact, not only does the syndrome involve several different 
phenotypes; the prevalence of the different phenotypes 
also varies according to ethnic groups [4–11].
Evidence from various geographic regions indicates 
that the metabolic features of PCOS are particularly 
influenced by ethnic background and behavioral char-
acteristics. For example, obesity is particularly com-
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relatively uncommon in Eastern Asia [16] and in Medi-
terranean countries [5–7]. Impaired fasting glucose, 
impaired glucose tolerance, and type 2 diabetes seem 
particularly common in India [17, 18] and in the U.S. 
[13, 14] and relatively uncommon in Mediterranean 
countries [6, 7]. A similar pattern has been reported for 
the prevalence of metabolic syndrome and dyslipidemia 
[7, 14, 19].
In contrast, only limited information is available 
regarding the phenotype distribution and the meta-
bolic expression of PCOS in some other regions, such 
as Brazil, a large country representing a range of ethnic 
backgrounds. Brazil also presents socio-economic dis-
parities among its five regions. Total Brazilian popula-
tion, according to 2020 national data, is of 211,755,692 
inhabitants, with 83% distributed in the Northeast, 
Southeast and South (https ://www.ibge.gov.br/estat 
istic as/socia is.html). Regarding education, inhabitants 
of the southeast region have the better access to educa-
tion, with 28.9% of population with 25 years old or more 
having concluded school, while the lowest index is in 
the northeast region, 23.5%. Regarding economic status, 
the median monthly income per person in the South is 
U$211.3, U$187.4 in Southeast, U$184.8 in Midwest, 
U$94.6 in North and U$ 93.7 in Northeast. However, 
there is great variation in incomes according to social 
classes, in the whole territory.
Therefore, the aim of the present systematic review 
and meta-analysis was to examine the available evidence 
regarding the prevalence of metabolic alterations in Bra-
zilian women with PCOS.
Methods
Search strategy and study selection
This systematic review and meta-analysis was registered 
in PROSPERO under number CRD42016038537. Pub-
Med, Cochrane Central Register of Controlled Trials, and 
Embase were searched for cross-sectional, case–control, 
cohort, and prevalence studies published until July, 2019 
and including populations from different regions of Bra-
zil. No limits were set on publication date or language. 
Medical subject headings (MeSH) used in the search are 
presented as Additional file  1. Additional searches were 
performed in recent review articles and original studies 
with a focus on PCOS.
Studies were selected for the present review if they pro-
vided a clear definition of the criteria used for diagnosis 
of PCOS and analyzed of at least one of the following 
variables: body mass index (BMI), waist circumference 
(WC), blood pressure, lipid profile, glucose, HOMA-IR, 
metabolic syndrome (MetS), diabetes mellitus (DM), 
prevalence of PCOS, and milder phenotypes.
Data extraction and quality control assessment
Two reviewers (RBR and PMS) independently screened 
titles/abstracts for selection of articles for full-text 
review. Disagreements were resolved by consensus 
discussion. The full text of selected articles was inde-
pendently reviewed by the two authors. If selected arti-
cles were published in other languages than English or 
Portuguese a translate site would be used. If data were 
duplicated or reported more than once, the most com-
plete study was chosen. If the required data were not 
located in the published article, authors were contacted 
to provide the missing information.
The following information was extracted from stud-
ies: name of authors, publication year, country, type of 
study, population characteristics, diagnostic criteria, 
total population, and outcomes of interest in PCOS and 
control group. Three authors extracted the data from 
each report independently. The Newcastle–Ottawa 
scale (NOS) was used to assess the quality of the obser-
vational studies included in the meta-analyses.
Statistical analysis
The standardized mean difference (SMD) with 95% con-
fidence interval (CI) was estimated using a DerSimo-
nian and Laird (DL) random effects model. A p value of 
less than 0.05 was considered as statistically significant. 
Variables of interest were included in the meta-analysis 
if they were present in at least two studies.
We assessed heterogeneity from the Mantel–Haen-
szel model and  I2 values (the percentage of variance in 
the pooled estimate due to between-study differences), 
with  I2 > 50% suggesting moderate heterogeneity and 
p < 0.10 in Cochran’s Q test indicating significant heter-
ogeneity[20]. The risk of publication bias was assessed 
using funnel plot graphics, analyzed both visually and 
with the Egger test. The significance of the intercept 
was evaluated by the t test, with p < 0.10 indicating sig-
nificant publication bias [21].
Statistical analyses were performed using R ver-
sion 3.4.3. (2017–11-30) (http://www.r-proje ct.org). 
The metafor package for doing meta-analysis was used 




Figure  1 provides details of the study selection. Our 
search yielded 4856 articles, of which 27 studies, all 
observational, were eligible for inclusion in the system-
atic review, 14 cross-sectional, 12 case–control stud-
ies and 01 cohort (Table 1). All articles were published 
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4856 potentially eligible studies 
identified and screened 
4781 excluded for not meeting eligibility 
criteria 
75 full-text articles assessed for 
eligibility 
48 excluded after full-text screening 
Reasons for exclusion:  
21 variables of interest or measures only 
available for stratified sub-groups  
18 participant selection according to a 
specific BMI class  
5 included adolescent population 
4 data reported more than once, the most 
complete study was included  
 
  
27 studies included in systematic 
review 
12 studies included in meta-
analysis of Brazil 
15 excluded in data extraction for:  
2 absence of standard deviation 
for variables of interest 
11 no control group for 
comparison 
2 variables of interest only 
available for PCOS phenotypes 
Fig. 1 PRISMA flow diagram of the study selection process
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between 2004 and 2019. Sample sizes ranged from 10 to 
288 in PCOS groups and 10 to 1,500 in control groups.
Qualitative data synthesis
Table  1 summarizes the characteristics of studies on 
Brazilian populations. Seven studies were from the 
Northeast region [23–29], thirteen studies were from 
the Southeast [30–42], five studies were from the South 
[43–47], and two studies were from the Midwest region 
[48, 49]. No data from the North region were available. 
All the studies used the Rotterdam criteria for diagnosis 
of PCOS, except by one [40]. In five studies, the control 
groups and PCOS participants were BMI-matched [25, 
33, 39, 41, 47]. Ten out of 27 studies had no control group 
for comparison [27–30, 34, 37, 38, 40, 48, 49] and thus 
these studies were not included in the meta-analyses. 
Another one study was excluded from the meta-analyses 
because the control group included participants who 
were hirsute or had irregular menses [36]. Two studies in 
which data on PCOS participants were presented only as 
PCOS phenotypes [35, 43] and other two studies that did 
not present SD values for the variables of interest[29, 34] 
were equally excluded from the meta-analyses.
In Brazilian women with PCOS, BMI ranged from 
24.2 to 31.9  kg/m2 (Table  2). In studies without a BMI-
matched control group, most PCOS groups had higher 
BMI than controls [23, 24, 31, 35, 42–46]. The prevalence 
of obesity in Brazilian women with PCOS diagnosed by 
Table 1 Characteristics of the studies included in the systematic review about Brazilian women with PCOS
a Data are from A phenotype PCOS vs controls
b Women included in the control group had similar complaints as the ones from the PCOS group, but did not fulfill the diagnostic criteria
c Data are from baseline
d Data are from A plus B phenotypes PCOS vs controls
*p < 0.05 between groups
Name, Year Region PCOS criteria Type of studies N (PCOS/controls) Age (PCOS/controls
BMI-unmatched studies
Avila et al. 2014 [30] Southeast Rotterdam Cross-sectional 100/– 25.7 ± 4.9/–
Azevedo et al. 2011 [23] Northeast Rotterdam Cross-sectional 113/242 26.2 ± 4.3/ 26.8 ± 5.0
Carvalho et al. 2017 [31] Southeast Rotterdam Case–control 86/86 31.1 ± 4.92/29.0 ± 7.04
Cerqueira et al. 2010 [24] Northeast Rotterdam Cross-sectional 56/54 26.2 ± 6.0/27.7 ± 6.1
Costa et al. 2012 [29] Northeast Rotterdam Cross-sectional 113/– 27.2 ± 4.5/–
de Medeiros et al. 2014 [48] Midwest Rotterdam Cross-sectional 288/– 26.9 ± 5.5/–
Gabrielli et al. 2012 [26] Northeast Rotterdam Cross-sectional 73/725 28.4 ± 6.5/31.0 ± 7.3*
Graff et al. 2017 [44] South Rotterdam Case–control 84/54 23.5 ± 6.3/26.2 ± 6.5
Kogure et al. 2012 [32] Southeast Rotterdam Case–control 20/19 27.8 ± 5.0/27.9 ± 5.2
Maciel et al. 2014 [34] Southeast Rotterdam Cross-sectional 97/– 24.9 ± 5.1/–
Melo et al.  2011a [35] Southeast Rotterdam Cross-sectional 132/146 26.6 ± 5.1/28.9 ± 0.5
Oliveira et al.  2013b [36] Southeast Rotterdam Case–control 42/18 27.4 ± 5.5/31.4 ± 6.1
Pedroso et al. 2012 [37] Southeast Rotterdam Cross-sectional 105/– 29 ± 4.4/–
Pontes et al. 2012 [38] Southeast Rotterdam Cross-sectional 189/– 24.9 ± 5.2/–
Radavelli-Bagatini et al. 2013 [45] South Rotterdam Case–control 80/1500 21.3 ± 0.6/22.7 ± 0.4
Ramos et al. 2015 [46] South Rotterdam Case–control 199/99 22 ± 6/25 ± 7
Santana et al.  2004c [40] Southeast NIH Cohort 21/– 27.2/–
Soares et al. 2016 [27] Northeast Rotterdam Cross-sectional 22/– 26 ± 6.0/–
Tavares et al. 2019 [28] Northeast Rotterdam Cross-sectional 111/– 18–39
Wanderley et al., 2018 [49] Midwest Rotterdam Cross-sectional 83/– 28.79 ± 5.85/–
Wiltgen et al.  2010d [43] South Rotterdam Case–control 195/25 22.3 ± 6.7/29.7 ± 4.29*
Xavier et al. 2018 [42] Southeast Rotterdam Case–control 97/99 30.5 ± 5.1/29.8 ± 7.1
BMI-matched studies
Costa et al., 2008 [25] Northeast Rotterdam Cross-sectional 57/37 25.5 ± 5.3/26.6 ± 5.4
Lauria et al. 2013 [33] Southeast Rotterdam Case–control 40/36 29 (25–34)/30(15–43)
Rocha et al. 2011 [39] Southeast Rotterdam Case–control 142/31 25.1 ± 5.4/27.5 ± 4
Simões et al. 2017 [41] Southeast Rotterdam Case–control 10/10 29.6 ± 1.2/28.6 ± 2.0
Wiltgen et al. 2009 [47] South Rotterdam Case–control 51/44 20.6 ± 5.1/28.9 ± 5.6*
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Table 2 Characteristics of Brazilian women with PCOS in the studies included in the systematic review
Name, 
Year
BMI (PCOS/controls) Waist circumference 
(cm) (PCOS /controls)









Avila et al. 
2014 [30]




29.3 ± 6.7/24.1 ± 4.4* 91.2 ± 15.7/77.1 ± 9.6* SBP: 114.8 ± 13.3/111.5 ± 10.7*
DBP: 72.6 ± 10.7/72.1 ± 10.3
TC (mmol/L):
4.82 ± 1.09/4.57 ± 1.19
HDL (mmol/L):




1.56 ± 0.91/1.13 ± 0.6 *








27.7 ± 5.4/ 24 ± 4.2* 84.5 ± 11.3/ 78.9 ± 10.0* SBP: 117.5 ± 11.9/104.0 ± 10.3*
DBP: 77.7 ± 9.8/68.7 ± 8.1*
TC (mmol/L):
4.57 ± 0.81/4.11 ± 0.76*
HDL (mmol/L):
1.16 ± 0.24/ 1.41 ± 0.43*
LDL (mmol/L):
2.29 ± 0.92/2.14 ± 0.75
TGL (mmol/L):
1.3 ± 0.78/0.94 ± 0.43*
4.88 ± 0.68/4.68 ± 0.41* 3.6 ± 3.7/1.9 ± 0.9*
Costa et al. 
2012 [29]










4.62 ± 0.68/– NA
de Medei-
ros et al. 
2014 [48]




24.2 (17.7–30.7)/ 24.1 
(18.1–30.1)
74 (56–92)/75 (60–90) SBP: 119 (99–139)/122 
(102–142)
DBP: 74 (60–88)/ 74 (59.5–89.5)
NA NA NA
Graff et al. 
2017 [44]
29.4 ± 6.4/27.2 ± 5.8* 86.6 ± 14.1/83.6 ± 12.3 SBP:118.2 ± 13.0/112.4 ± 11.1*
DBP:77.4 ± 9.9/72.8 ± 10.0*
TC (mmol/L):
4.49 ± 0.89/4.5 ± 0.79
HDL (mmol/L):
1.18 ± 0.31/1.31 ± 0.28*
LDL (mmol/L):









28.7 ± 4.4/27.1 ± 5.1 NA NA TC (mmol/L):
5.42 ± 1.24/5.47 ± 1.19
HDL (mmol/L):
1.38 ± 0.31/1.52 ± 0.28
LDL (mmol/L): 
3.29 ± 0.92/3.4 ± 0.96
TGL (mmol/L): 
1.65 ± 0.93/1.19 ± 0.75*
5.82 ± 0.99/5.73 ± 1.09 2.3 ± 2.3/1.6 ± 0.8*
Maciel et al. 
2014 [34]





TGL (mmol/L): 1.3 ± 0.7/–
4.95 ± 0.57/– 3.8 ± 3.3/–




BMI (PCOS/controls) Waist circumference 
(cm) (PCOS /controls)








Melo et al. 
 2011a 
[35]
31.3 ± 8.7/24.4 ± 4.9* 98.6 ± 17.7/84.8 ± 12.4 SBP:
121.5 ± 15.2/111.5 ± 10.8*
DBP:
7 8 ± 10.4/71.7 ± 8.2*
TC (mmol/L): 
4.76 ± 1.04/4.93 ± 0.84
HDL (mmol/L): 
1.16 ± 0.27/1.41 ± 0.28*
LDL (mmol/L): 
2.9 ± 0.92/2.82 ± 0.72
TGL (mmol/L): 
1.49 ± 0.82/0.95 ± 0.44*





30.2 ± 6.5/27.1 ± 6.2 NA SBP:
111.8 ± 12.0 / 107.3 ± 15.0
DBP:
70.2 ± 9.0/71 ± 13.5
TC (mmol/L): NA
HDL (mmol/L): 
1.3 ± 0.38/1.49 ± 0.35
LDL (mmol/L): NA
TGL (mmol/L): 
1.32 ± 0.91/1.31 ± 0.74















5.04 ± 1.08/– NA
Pontes et al. 
2012 [38]
31.8 ± 7.6/– 92.2 ± 16.0 SBP: 116.3 ± 14.4/–
DBP: 75.1 ± 10.4/–












31.0 ± 7.9/23.4 ± 4.6* 92.2 ± 18.8/74.5 ± 10.2* SBP: 124.6 ± 19.9/111.5 ± 13.0*
DBP: 79.2 ± 12.5/71.8 ± 10.6*
TC (mmol/L):
4.81 ± 1.16/4.24 ± 0.9*
HDL (mmol/L): 
1.32 ± 0.28/1.52 ± 0.36*
LDL (mmol/L): 
2.95 ± 0.98/2.09 ± 0.72*
TGL (mmol/L): NA
NA NA
Ramos et al. 
2015 [46]












4.48 ± 0.59/– NA
Soares et al. 
2016 [27]











29.9 ± 5.28/– 92.15 ± 10.72/– SBP: 123.15 ± 18.38/–
DBP: 79.13 ± 11.00/–







4.87 ± 0.36/– NA




BMI (PCOS/controls) Waist circumference 
(cm) (PCOS /controls)












31 ± 7.98/ 26.97 ± 3.6* 93.79 ± 18.81/ 
79.83 ± 8.37*
SBP: 123.1 ± 16.9/115.2 ± 9.5*
DBP: 78.9 ± 12.3/73.6 ± 8.3
TC (mmol/L): 
4.72 ± 1.13/4.27 ± 0.95
HDL (mmol/L): 
1.25 ± 0.29/1.42 ± 0.35
LDL (mmol/L): 2.85 ± 0.96/ 
2.47 ± 0.81
TGL (mmol/L): 1.12 
(0.76–1.6)/ 0.68 (0.47 
– 1.05)*
5.02 ± 1.19/ 4.92 ± 0.45 4.53 (2.6–7.7)/ 2.14 
(1.4–3.1)*
Xavier et al. 
2018 [42]
28.8 ± 8.1/ 22.9 ± 5.9* 97.0(18.0)/ 82.4(20.0)* NA TC (mmol/L): 4.92 ± 0.94/ 
4.55 ± 0.83*
HDL (mmol/L): 1.19 (0.49) 
/ 1.39 (0.49)*
LDL (mmol/L): 
2.97 ± 0.82/2.58 ± 0.72*
TGL (mmol/L): 1.11 (0.97) 
/0.93 (0.44)*
6.95 ± 11.2/5.78 ± 7.14 2.8 (1.8)/1.59 (1.2)*
BMI-matched studies
Costa et al. 
2008 [25]
27.6 ± 5.8/26.7 ± 4.9 87.8 ± 14.3/83.6 ± 10.1 SBP: 118.9 ± 15.2/113.8 ± 10.9
DBP: 79.9 ± 8.9/73.4 ± 10.2*
TC (mmol/L): 
4.37 ± 0.62/4.11 ± 0.83
HDL (mmol/L): 
1.23 ± 0.34/ 1.54 ± 0.27*
LDL (mmol/L): 
2.56 ± 0.65/2.21 ± 0.72*
TGL (mmol/L): 
1.16 ± 0.55/1.06 ± 0.68
Lauria et al. 
2013 [33]
27.64 ± 5.43/25.99 ± 5.51 91 (83–101)/94 (83–103) SBP:
120 (110–120)/120 (110–120)
DBP:





HDL (mmol/L): 1.11 (0.88–
1.29)/1.01 (0.85–1.14)
LDL (mmol/L): 2.77 (2.3–
3.26)/2.25 (1.76–2.87)*
TGL (mmol/L): 0.91 (0.73–
1.22)/0.8 (0.65–1.06)
Rocha et al. 
2011 [39]
29.1 ± 6.17/27.4 ± 6.9 NA NA TC (mmol/L): 
4.68 ± 0.78/4.28 ± 0.4
HDL (mmol/L): 
1.23 ± 0.45/1.51 ± 0.2*
LDL (mmol/L): 
2.87 ± 0.65/2.63 ± 0.58
TGL (mmol/L): 








29.5 ± 7.5/29.4 ± 5.4 90.6 ± 16.1/ 85.5 ± 11.6* NA TC (mmol/L): 4.85 ± 1.11 / 
4.2 ± 0.8*
HDL (mmol/L): 1.35 ± 0.27 
/ 1.32 ± 0.3
LDL (mmol/L) 
3.07 ± 0.97/2.46 ± 0.69*
TGL (mmol/L): 1.1 (0.77–
1.48)/0.73 (0.54–1.21)*
a Data are from A phenotype PCOS vs controls
b Women included in the control group had similar complaints as the ones from the PCOS group, but did not fulfill the diagnostic criteria
c Data are from baseline
d Data are from A plus B phenotypes PCOS vs controls
* p < 0.05 between the groups. Continuous metabolic variables are not available from Tavares et al. 2019 [24]
Page 8 of 16Spritzer et al. Diabetol Metab Syndr           (2021) 13:18 
Rotterdam criteria was reported in eight studies [26, 28, 
34, 39, 42, 46, 48, 49]. Except for one study with non-
selected women from primary healthcare services [26] 
in which the prevalence of obesity was similar to that of 
the general Brazilian female population [50] in the other 
seven studies the prevalence of obesity ranged from 31.6 
to 56.6 in the Midwest, Southeast, and South, showing 
quite higher values than those expected for the Brazilian 
female population (17.9% for women aged 25–34  years) 
[50] (Table 3).
Table 2 also presents WC, blood pressure, glucose, and 
lipid profile of Brazilian women with PCOS and con-
trol populations. Only three studies [26, 37, 44] did not 
observe a larger WC in PCOS participants vs. controls. 
Thirteen studies had no data on WC or a control group 
for comparison.
Eleven Brazilian studies reported blood pressure data 
in PCOS and control groups [23–26, 33, 35, 36, 43–46]. 
Of these studies, eight showed a higher systolic (SBP) 
or diastolic blood pressure (DBP) in PCOS [23–25, 35, 
43–46].
Fasting glucose was measured in 23 studies [23–25, 27, 
29, 31–44, 46–49] (Table 2). Glucose levels ranged from 
4.38 to 6.95 mmol/L in Brazilian women with PCOS and 
from 4.25 to 5.78 in controls. In three studies [23, 24, 
37] PCOS groups had higher glucose levels than control 
groups. Eleven studies had no data on glucose levels or a 
control group for comparison.
Impaired fasting glucose (IFG, fasting glucose between 
5.6 and 6.9  mmol/L) [46] and/or impaired glucose 
tolerance (IGT, glucose levels between 7.8 and 11.1 mmol/L 
at 120 min after the oGTT) [43] was found in only two stud-
ies from the South region (9.7 and 11.3%) and in one from 
the Northeast (7.2% [28]). Only one study (Table 3) reported 
prevalence of type 2 diabetes in Brazilian women with 
PCOS. Out of 195 patients, 3.6% were diabetic.
HOMA-IR, a marker of insulin resistance, was available 
in 14 studies, and twelve studies also compared HOMA-
IR values in PCOS and controls. In ten studies [24, 25, 31, 
32, 35, 39, 42–44, 47] HOMA-IR was higher in women 
with PCOS than in controls (Table  2). Metabolic syn-
drome was evaluated in Brazilian women with PCOS 
in the Northeast, Southeast, and South and showed a 
homogeneous prevalence among the regions, ranging 
between 24.6 and 42.9% [28–30, 34, 37, 43, 46] (Table 3).
Regarding lipid profile, 19 studies on Brazilian women 
with PCOS showed TGL levels ranging from 0.91 to 
1.65 mmol/L, and in 12 of them values for control groups 
ranged from 0.68 to 1.32  mmol/L (Table  2). TGL lev-
els were higher in PCOS than controls in seven out of 
these 12 studies [23, 24, 32, 35, 42, 43, 47]. Twenty-one 
Brazilian studies assessed HDL cholesterol levels, and 
14 of them compared HDL values in PCOS (1.01–
1.38  mmol/L) vs. controls (1.01–1.54  mmol/L)[23–25, 
32, 33, 35, 36, 39, 42–47] (Table 2). In nine of these stud-
ies, HDL was significantly lower in PCOS than in con-
trols [23–25, 35, 39, 42, 44–46]. LDL levels ranged from 
2.29 to 3.29 mmol/L in PCOS women from 18 Brazilian 
studies and from 2.09 to 3.4 mmol/L in controls from 11 
studies (Table 2). Five studies [25, 33, 42, 45, 47] reported 
Table 3 Prevalence of obesity, dyslipidemia, metabolic syndrome, prediabetes and diabetes 2 in Brazilian women with PCOS
Rotterdam criteria for all studies
a Lower HDL: ≤ 50
b Higher TGL: ≥ 150
c Prediabetes: IFG and/or IGT
d only data of adult women with PCOS were extracted
Study N Region Obesity (%) Dyslipidemia  (%) 
↓  HDLa





Avila et al. 2014 [30] 100 Southeast 36
Costa et al. 2012 [29] 113 Northeast 76.1 33.6 31
de Medeiroset al. 2014 [48] 288 Midwest 44.3
Gabrielli et al. 2012 [26] 73 Northeast 13.7
Maciel et al. 2014 34 97 Southeast 42.3 52.6 22.7 26.8
Pedroso et al. 2012 [37]d 105 Southeast 68.6 5.3 42.9
Ramos et al. 2015 [46] 199 South 56.6 17.8 24.6 9.7
Rocha et al. 2011 [28] 142 Southeast 31.6 57.6 28.3
Tavares et al. 2019 [28] 111 Northeast 44.1 54.1 35.1 33.6 7.2
Wanderley et al. 2018 [49] 83 Midwest 56.62
Wiltgen et al. 2010 [43] 195 South 52.5 58.8 22.9 31.3 11.3 3.6
Xavier,et al., 2018 [43] 97 Southeast 42.3
Page 9 of 16Spritzer et al. Diabetol Metab Syndr           (2021) 13:18  
LDL to be higher in PCOS. Eighteen studies with Brazil-
ian women with PCOS assessed TC levels and 12 com-
pared PCOS with controls, with mean values ranging 
from 4.37 to 5.42 mmol/L in PCOS and from 4.11 to 5.47 
in controls (Table 2). Five studies showed higher TC lev-
els in the PCOS group compared with the control group 
[24, 33, 42, 45, 47]. Seven studies assessed the prevalence 
of dyslipidemia in the Northeast, Southeast, and South 
and showed homogeneous values among the regions, for 
both lower HDL-cholesterol (ranging between 52.6 and 
76.1%) and higher triglycerides (from 5.3 to 35%).
Three studies evaluating referral populations assessed 
the prevalence of PCOS phenotypes [28, 35, 43]. Pheno-
types A + B were more prevalent in these studies (66.4, 
81 and 65.8%, respectively).
Quantitative data synthesis and meta-analysis
Of 27 studies, 12 articles meeting eligibility criteria were 
included in the meta-analysis [23–25, 31, 32, 39, 41, 
42, 44–47], for a total of 995 PCOS and 2,275 control 
women. All used the Rotterdam criteria to define PCOS. 
NOS score was 9 in seven studies, 8 in two, 7 in two, and 
6 in another one (Table 4).
BMI
Only BMI-unmatched studies were considered for anal-
ysis. Data from seven studies were analyzed [23, 24, 31, 
32, 44–46] including 638 PCOS and 2,054 controls. The 
PCOS group had higher BMI levels than controls (SMD 
0.67, 95% CI, 0.29, 1.05). Between-study heterogeneity 
was high  (I2 = 91%, p < 0.001) (Fig. 2a).
Waist circumference
As for BMI, only BMI-unmatched studies were consid-
ered for analysis of waist circumference. Five studies [23, 
24, 44–46] with 532 PCOS and 1,949 control participants 
were considered. The PCOS group had higher waist 
circumference vs. the control group (SMD 0.88, 95% 
CI 0.40, 1.37). Between-study heterogeneity was high 
 (I2 = 93% p = 0.001) (Fig. 2b).
Blood pressure
Five studies entered the meta-analysis of blood pressure 
[23–25, 44, 45] with 390 PCOS and 1887 control par-
ticipants. Higher SBP (SMD 0.66, 95% CI 0.30, 1.01) and 
DBP levels (SMD 0.55, 95% CI 0.24, 0.87) were observed 
in women with PCOS than in controls  (I2 = 83%, p < 0.001 
for SBP and  I2 = 81%, p = 0.0001 for DBP) (Fig. 2c and d).
Glucose
Ten studies were included for glucose meta-analysis [23–
25, 32, 39, 41, 42, 44, 46, 47] including 829 PCOS and 689 
control participants. Glucose levels were higher in the 
PCOS group (SMD 0.21, 95% CI 0.04, 0.38) when com-
pared with controls, with moderate between-study het-
erogeneity  (I2 = 54.8%, p = 0.011) (Fig. 3a).
HOMA‑IR
HOMA-IR was analyzed in four studies [23, 25, 32, 39], 
for a total of 275 PCOS and 141 controls. HOMA-IR was 
higher in PCOS vs. controls (SMD 0.78, 95% CI 0.52, 
1.04), with low between-study heterogeneity  (I2 = 26%, 
p = 0.23) (Fig. 3b).
Lipids
Data from five studies were available for TGL analy-
sis [23–25, 32, 39], including 388 PCOS and 383 con-
trol participants. TGL levels were higher in the PCOS 
group (SMD of 0.39, 95% CI 0.14, 0.64), with moder-
ate between-study heterogeneity  (I2 = 63%, p = 0.079) 
(Fig. 4a). Eight studies were included in the HDL meta-
analysis [23–25, 32, 39, 44, 45, 47], with 603 PCOS and 
1,981 controls. HDL levels were lower in the PCOS 
group (SMD − 0.56, 95% CI − 0.78, − 0.34) when com-
pared with controls. Between-study heterogeneity 
was moderate  (I2 = 68%, p = 0.006) (Fig.  4b). LDL data 
were included from eight studies [24, 25, 32, 39, 42, 44, 
45, 47] with 587 PCOS and 1,838 controls. LDL levels 
were higher in PCOS (SMD 0.45 95% CI 0.17, 0.74). 
Between-study heterogeneity was high  (I2 = 80.31%, 
p =  < 0.0001) (Fig.  4c). Nine studies compared total 
cholesterol levels in PCOS and controls [23–25, 32, 
39, 42, 44, 45, 47] for a total of 700 PCOS and 2080 
Table 4 Newcastle–Ottawa quality (NOS) assessment scale 
for studies included in the meta-analysis
Quality of selection (minimum 1–maximum 4 stars); Comparability (minimum 
0–maximum 2 stars); Exposure (minimum 1–maximum 3 stars)
Author Year Selection Comparability Exposure
Azevedo (23) 2011 **** ** ***
Carvalho (31) 2017 **** ** ***
Cerqueira (24) 2010 ** * ***
Costa (25) 2008 *** * ***
Graff (44) 2017 **** * ***
Kogure (32) 2012 **** ** ***
Radavelli − Bagatini (45) 2013 **** * ***
Ramos (46) 2015 **** ** ***
Rocha (39) 2011 **** ** ***
Simões (41) 2017 **** ** ***
Wiltgen (47) 2009 **** ** ***
Xavier (42) 2018 *** * ***
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controls. TC levels were higher in PCOS (SMD 0.40 
95% CI 0.24, 0.57) than control participants, with mod-
erate between-study heterogeneity  (I2 = 52%, p = 0.02) 
(Fig. 4d).
Publication  bias may have occurred in comparisons 
of PCOS vs. controls in LDL analysis  (Fig.  5i). Con-
versely, no publication bias was detected in any other 
comparisons (p >  = 0.10; Fig. 5a–h and j).
Discussion
PCOS is a complex condition that affects both the repro-
ductive and the metabolic systems. In this meta-analysis 
including 12 cross-sectional and case–control studies, 
for a total of 995 PCOS and 2275 women from Brazil, 
BMI, waist circumference, blood pressure, glucose, and 
HOMA-IR were found to be higher in participants with 
PCOS. Lipid profile was more adverse than that found 
in non-PCOS women. Even though only observational 
Fig. 2 Forest plot showing a BMI, b waist circumference, c systolic blood pressure and d diastolic blood pressure
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studies including mostly small samples were examined, 
the evidence indicates that women with PCOS from dif-
ferent regions of Brazil have a worse cardiometabolic 
profile than women without PCOS. In addition, the sys-
tematic review of 27 observational studies with PCOS 
women from Brazil indicates that metabolic comorbidi-
ties, such as obesity, metabolic syndrome and IFG/IGT 
are prevalent in Brazilian women with PCOS with no 
important regional differences. To the best of our knowl-
edge, this is the first systematic review and meta-analysis 
evaluating metabolic characteristics of women with 
PCOS in the different regions of Brazil.
Despite the efforts to assess the impact of ethnic-
ity and sociocultural backgrounds on the metabolic 
traits of PCOS by comparing different populations, very 
few data are available regarding Latin American coun-
tries. In Brazil, the overall ancestry proportion has been 
described as 0.62 European, 0.21 African and 0.17 Amer-
indian [51, 52]. However, ancestry proportions seem to 
differ according to region, as indicated by self-reported 
Fig. 3 Forest plot showing a fasting glucose, b HOMA-IR
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Fig. 4 Forest plot showing a TGL, b HDL-Chol, c LDL-Chol, d total cholesterol
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skin color rates, in which lower rates of white are found 
in the North and Northeastern regions (23 and 29% 
respectively) compared to the South, Southeast and Mid-
west (78, 55 and 48%, respectively) (sidra.ibge.gov.br/
Tabela/3175 – accessed on 06/24/2020). Although these 
genetic backgrounds could impact the phenotypic het-
erogeneity of PCOS, the evidence emerging from the pre-
sent study rather suggests similarities in metabolic traits 
throughout the different regions of the country, a finding 
that could potentially inform public health care systems, 
preventive programs, and policies targeting women with 
PCOS in Brazil.
In the present systematic review and meta-analysis, 
women with PCOS from Brazil had higher BMI and 
worse metabolic status. Analysis of the available data 
showed that in women with PCOS, obesity, metabolic 
syndrome, and IFG/IGT were more frequent than in Bra-
zilian women from the general population of same age 
[50]. Of note, most of these studies were from referral 
populations, which may have influenced the prevalence 
of comorbidities at least to a certain extent [53].
Fig. 5 Funnel plots for risk of publication bias for a BMI, b waist circumference, c systolic blood pressure, d diastolic blood pressure, e glucose, f 
HOMA-IR, g TGL, h HDL-chol, i LDL-chol, j total cholesterol
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While the current information on the frequency of 
obesity in women with PCOS from different countries 
comes from only a few studies, generally with a small 
number of participants, or from studies reporting obe-
sity as a secondary outcome, the present data could 
indicate that the prevalence of obesity in Brazilian 
women with PCOS, varying from 31.6 to 56.6%, may 
be close to that of Scandinavian countries (42% [54]; 
35% [55]), and half way between that observed in U.S. 
women with PCOS diagnosed with Rotterdam criteria 
(65%) [11, 15] and that found in Mediterranean coun-
tries (8 and 31%) [6, 7, 11]. The prevalence of metabolic 
syndrome (24.6–42.9% in Brazilian women with PCOS) 
seems to be  similar to  that found in the U.S. (34.6% 
[15]; 43% [13]), and much higher than that observed in 
Mediterranean countries (10% [6]; 6.6% [7]).
The data regarding type 2 diabetes were too few for 
analysis, with only one study reporting a prevalence of 
diabetes of 3.6% in 195 Brazilian women with PCOS. 
Thus, further studies are needed in order to determine 
the frequency of diabetes in women with PCOS across 
the country [56]. In turn, the prevalence of impaired 
fasting glucose in PCOS women from the South and 
Northeast of Brazil was similar to that of Mediterra-
nean countries [7] and lower than that observed in the 
U.S. [12–14].
Taken together, these data suggest that PCOS-related 
metabolic alterations are less prevalent in Brazil than 
in the U.S., where the mean body weight of the general 
population is higher than in most other countries [57]. 
Also, additional studies are warranted, covering other 
underrepresented regions, such as the North of Brazil.
Another metabolic feature of PCOS is insulin resist-
ance, with higher risk of impaired glucose tolerance, 
type 2 diabetes, and gestational diabetes [58–60]. A 
recent study showed a pooled PCOS prevalence of 24% 
(95% CI 15; 34) in adolescent and adult women with 
type 1 diabetes, which is markedly higher than the 
general population [61]. In our systematic review and 
meta-analysis, we found Brazilian women with PCOS 
presented increased HOMA-IR. Previous studies have 
found that women with PCOS, as opposed to controls, 
have significantly decreased insulin sensitivity with 
increasing BMI [58, 62] and low-grade chronic inflam-
mation [63, 64]. Previous meta-analyses including dif-
ferent populations have shown higher odds for MetS 
among women with PCOS [65, 66]. However, in both 
studies very few data from Latin American populations 
were available. In turn, due to the paucity of available 
data, additional studies assessing prediabetes and dia-
betes and distinct PCOS phenotypes in different coun-
tries of Latin America are warranted and could produce 
relevant information for the primary and secondary 
prevention of these PCOS-related metabolic comorbid-
ities in the region.
Considering the dearth of information, the present 
systematic review and meta-analysis provides a com-
prehensive overview of metabolic and anthropometric 
variables among women diagnosed with PCOS in Bra-
zil. A major strength of our study is the extensive search 
strategy, covering the main databases to avoid missing 
any relevant information, with active search for studies 
published also in Portuguese language. Limitations are 
the small number of studies in view of the size of the 
region, the small sample sizes, and the possible sources 
of heterogeneity across the studies. However, there are 
no other similar analyses in the literature. Thus, this 
study represents the first evidence to characterize the 
metabolic profile of women with PCOS in the context 
of ethnicities and sociocultural backgrounds in Brazil.
Conclusions
The present results indicate that women with PCOS 
from different regions of Brazil have worse anthropo-
metric and metabolic profiles than women from the 
same regions without PCOS. The prevalence of meta-
bolic changes is intermediate in Brazil in comparison 
with other countries. Regarding the prevalence of dia-
betes, the evidence produced is not conclusive, sug-
gesting that additional studies are warranted and could 
produce invaluable results in the context of PCOS.
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